tucatinib,trastuzumab,trastuzumab deruxtecan
seagen,daiichi sankyo,astrazeneca
['trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 't-dxd', 'tucatinib']
can we split by subgroups here? t-dxd for ihc 3+ or ras mt or prior her2 agent and tucatinib/trastuzumab for 2+, perhaps as initial line (but only for ras wt)? #asco23 
Medical oncologist: GI cancers & cancer of unknown primary + high quality & value-based cancer care delivery. @UTexasValue MSHCT student. Tweets mine.